Announcement time of this financial report: 2023-10-27 17:01:10
Tianchen Medical (Stock Code: 688013) is a company specializing in products needed at critical moments of surgery. Its main business includes various stapler products in the fields of cardiothoracic surgery, gastrointestinal surgery, hepatobiliary spleen and pancreas surgery, general surgery, urology and so on. These products include tubular stapler, endoscopic stapler, linear cutting stapler, purse stapler and linear suture stapler. The company is committed to scientific diagnosis, accurate treatment and scientific rehabilitation, with the aim of improving the quality of life of patients.
In terms of assets and liabilities, Tianchen Medical's total assets at the end of the third quarter of 2023 was 587 million yuan, an increase compared with 543 million yuan at the end of last year. The total liabilities were 35.2901 million yuan, a slight increase compared with 35.0447 million yuan at the end of last year. The net worth was 552 million yuan, up from 508 million yuan at the end of last year. The asset-liability ratio was 6.01%, down from 6.45% at the end of the previous year.
In terms of profit, the company's operating income in the third quarter of 2023 was 182 million yuan, an increase from 168 million yuan in the same period last year. The operating profit was 35.4571 million yuan, a slight increase compared with 35.2607 million yuan in the same period last year. The operating cost was 78.3666 million yuan, an increase from 66.6028 million yuan in the same period last year. The net profit was 33.1119 million yuan, up from 31.7921 million yuan in the same period last year. The gross profit margin was 56.87%, down from 60.42% in the same period last year. The net interest rate was 18.22%, down from 18.89% in the same period last year. The return on equity (ROE) was 6.24%, which was basically the same as 6.23% at the end of last year.
In terms of cash flow, the net cash flow generated by operating activities was 49.1879 million yuan, an increase compared with 45.3348 million yuan in the same period last year. Cash inflows from operating activities totaled 212 million yuan, up from 199 million yuan in the same period last year. Cash outflow from operating activities totaled 162 million yuan, up from 154 million yuan in the same period last year.
To sum up, the overall operating situation of Tianchen Medical in the third quarter of 2023 was stable, with an increase in operating income and net profit, a decline in asset-liability ratio and a good cash flow. At the same time, the company continues to increase its R & D investment, totaling 24.6863 million yuan, accounting for 13.59% of business income, which shows that the company attaches importance to scientific and technological innovation and product research and development.
For investors, Tianchen Medical has a stable operating condition and good cash flow. At the same time, the company's investment in R & D also shows its confidence in future development. Therefore, investors can consider it as a long-term investment choice. However, investors also need to note that the company's gross profit margin and net profit margin have declined, which may be due to the increase in costs or the intensification of market competition. Investors need to pay more attention to the impact of these factors on the company's future profitability.
This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.